Physician profile
Chris J Narsesian
NPI 1073159513
$2,680.46
in general payments reported to CMS, 2019-2025
19 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129 · 2022: $503 · 2023: $229 · 2024: $591 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.76 |
| Education | $203.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $531.95 | 2021-2025 | |
| Janssen Biotech, INC. | $386.24 | 2021-2025 | Tremfya |
| Genzyme Corporation | $298.87 | 2022-2025 | |
| Amgen INC. | $286.55 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $197.85 | 2021-2025 | Libtayo, Dupixent |
| E.R. Squibb & Sons, L.L.C. | $163.90 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $131.70 | 2022-2025 | |
| Pfizer INC. | $95.31 | 2021-2025 | |
| Galderma Laboratories, L.P. | $86.77 | 2021-2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $72.00 | 2022 | |
| Leo Pharma INC. | $71.81 | 2023-2025 | Anzupgo, Adbry |
| Ucb, INC. | $65.31 | 2025 | Bimzelx |
| Hill Dermaceuticals, INC. | $64.26 | 2024 | Tolak |
| Lilly USA, LLC | $47.97 | 2021-2025 | Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $43.36 | 2024-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $40.08 | 2023-2024 | Puraply |
| Biofrontera INC. | $38.36 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Convatec INC. | $35.57 | 2024 | |
| Kerecis Limited | $22.60 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Narsesian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.